Leukemia  >>  Iomab-B (I-131-apamistamab) 
Welcome,         Profile    Billing    Logout  

2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iomab-B (I-131-apamistamab) / Actinium, Immedica
SIERRA, NCT02665065: Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Checkmark Top line data from SIERRA trial for r/r AML
Oct 2022 - Oct 2022: Top line data from SIERRA trial for r/r AML
Checkmark Data from SIERRA trial for r/r AML
Apr 2022 - Apr 2022: Data from SIERRA trial for r/r AML
Checkmark Patient enrollment completed in P3 SIERRA trial for AML
More
Active, not recruiting
3
153
Canada, US
Iomab-B, Conventional Care, HCT
Actinium Pharmaceuticals
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
06/22
12/26
NCI-2018-01788, NCT03670966: 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Suspended
1/2
30
US
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, At 211 MAb BC8-B10, APAMISTAMAB-B10-ASTATINE AT-211, Cyclophosphamide, (-)-Cyclophosphamide, Asta B 518, B-518, WR-138719, Total-Body Irradiation, Total Body Irradiation, SCT_TBI, Whole Body Irradiation, Whole-Body Irradiation, TBI, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Bone Marrow Transplantation, Bone Marrow Grafting, BMT, Mycophenolate Mofetil, 115007-34-6, MMF, Cellcept, Recombinant Granulocyte Colony-Stimulating Factor, 143011-72-7, Recombinant Colony-Stimulating Factor 3, rhG-CSF, Fludarabine Phosphate, 2-F-ara-AMP, Beneflur, Fludara, Fludarabine-5''-Monophosphate, SH T 586, Tacrolimus, Prograf, Protopic, FK 506, FK-506, Tacforius, Bone Marrow Aspiration and Biopsy, Biospecimen Collection, Biological Sample Collection
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
06/25
03/27

Download Options